Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

31.08
BATS BZX Real-Time Price
As of 12:35pm ET
 -0.69 / -2.17%
Today’s Change
16.64
Today|||52-Week Range
42.49
+7.77%
Year-to-Date
Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016
Jan 13 / MotleyFool.com - Paid Partner Content
3 Companies Whose Sales Could Double in 2017
Jan 07 / MotleyFool.com - Paid Partner Content
CT Financial Advisors LLC Buys Alphabet Inc, Alphabet Inc, United Therapeutics Corp, ...
Jan 12 / GuruFocus News - Paid Partner Content
Acadia Pharmaceuticals' Alzheimer's Data Raises Some Questions
Jan 06 / MotleyFool.com - Paid Partner Content
Top Stocks to Buy in 2017
Jan 07 / MotleyFool.com - Paid Partner Content
Here's Why Acadia Pharmaceuticals Inc. Stock Is Up Today
Jan 04 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close31.77
Today’s open31.26
Day’s range30.16 - 31.62
Volume63,372
Average volume (3 months)2,614,391
Market cap$3.8B
Dividend yield--
Data as of 12:35pm ET, 01/17/2017

Growth & Valuation

Earnings growth (last year)-71.58%
Earnings growth (this year)-44.15%
Earnings growth (next 5 years)+15.31%
Revenue growth (last year)-49.17%
P/E ratioNM
Price/Sales58,810.80
Price/Book16.21

Competitors

 Today’s
change
Today’s
% change
AGNPRAAllergan plc-11.78-1.50%
PTHNPatheon NV-0.19-0.67%
ALNYAlnylam Pharmaceutic...-3.46-8.32%
TAROTaro Pharmaceutical ...-0.23-0.22%
Data as of 12:35pm ET, 01/17/2017

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)-$0.66
Annual revenue (last year)$61.0K
Annual profit (last year)-$164.4M
Net profit margin-269,578.69%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stephen R. Davis
Vice President-Technology Development &
Operations
James A. Nash
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs